We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

89 hedge funds and large institutions have $229M invested in Cue Biopharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.07% less ownership

Funds ownership: 2.13% → 2.06% (-0.07%)

5% less capital invested

Capital invested by funds: $241M → $229M (-$12M)

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

8% less funds holding

Funds holding: 97 → 89 (-8)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

76% less call options, than puts

Call options by funds: $732K | Put options by funds: $3.06M

Holders
89
Holders Change
-8
Holders Change %
-8.25%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
31
Reduced
33
Closed
14
Calls
$732K
Puts
$3.06M
Net Calls
-$2.33M
Net Calls Change
+$35K

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$8.69M
2
AR
Advisory Research
Illinois
+$3.51M
3
NCM
Nantahala Capital Management
Connecticut
+$2.71M
4
SMH
Sanders Morris Harris
Texas
+$2.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$5.66M
2
PM
Prosight Management
Texas
-$4.8M
3
WP
Woodline Partners
California
-$4.22M
4
Millennium Management
Millennium Management
New York
-$3.9M
5
Morgan Stanley
Morgan Stanley
New York
-$3.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$33M +$2.71M +6,574 +8%
CA
2
Corriente Advisors
Texas
$31.1M +$8.69M +21,127 +33%
BlackRock
3
BlackRock
New York
$27.4M +$1.16M +2,824 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$19M +$1.51M +3,664 +8%
SPC
5
Slate Path Capital
New York
$18.1M – – –
State Street
6
State Street
Massachusetts
$16.7M -$288K -699 -2%
Goldman Sachs
7
Goldman Sachs
New York
$7.35M +$1.22M +2,958 +17%
PM
8
Prosight Management
Texas
$6.79M -$4.8M -11,660 -39%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$5.93M +$760K +1,847 +13%
RSWM
10
Robertson Stephens Wealth Management
California
$5.84M -$75.3K -183 -1%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$4.47M +$211K +513 +4%
SMH
12
Sanders Morris Harris
Texas
$4.38M +$2.18M +5,298 +82%
6CM
13
683 Capital Management
New York
$4.12M +$239K +581 +5%
Northern Trust
14
Northern Trust
Illinois
$4.04M -$179K -435 -4%
Two Sigma Investments
15
Two Sigma Investments
New York
$3.95M -$14K -34 -0.3%
Morgan Stanley
16
Morgan Stanley
New York
$3.89M -$3.09M -7,498 -41%
AR
17
Advisory Research
Illinois
$3.12M +$3.51M +8,533 New
WP
18
Woodline Partners
California
$2.47M -$4.22M -10,243 -60%
Charles Schwab
19
Charles Schwab
California
$2.35M +$113K +275 +4%
CC
20
Carlson Capital
Texas
$1.89M +$955K +2,320 +82%
PAWC
21
P.A.W. Capital
Connecticut
$1.71M – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.34M -$67.9K -165 -4%
N
23
Nuveen
North Carolina
$1.25M -$544K -1,323 -28%
VC
24
Voss Capital
Texas
$1.22M -$1.66M -4,024 -55%
Millennium Management
25
Millennium Management
New York
$956K -$3.9M -9,471 -78%
1
2 3 4 5

CUE Hedge Fund Activity: Q1 2021 in Review

89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2021, worth a combined $229M — down 5% from $241M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CUE and 6 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 31 added.

The largest buyer was Corriente Advisors, adding an estimated $8.69M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $5.66M sold.

  • 89 institutional investors held Cue Biopharma (CUE) as of Q1 2021, down from 97 in Q4 2020.
  • Funds reported $229M of Cue Biopharma stock for Q1 2021, down 5% quarter-over-quarter.
  • 6 funds opened new Cue Biopharma positions in Q1 2021 and 14 closed out, a net change of -8 holders.
  • The largest Cue Biopharma buyer in Q1 2021 was Corriente Advisors, an estimated $8.69M added.
  • The largest Cue Biopharma seller in Q1 2021 was Avoro Capital Advisors, an estimated $5.66M sold.

Based on aggregated 13F filings for Q1 2021.